Kyungwha Lee

Title: Kyungwha Lee: Innovator in Allergy Treatment

Introduction

Kyungwha Lee is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative treatments for allergic diseases. His work focuses on enhancing the safety and efficacy of therapeutic agents.

Latest Patents

Kyungwha Lee holds a patent for a "Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of IgE Fc receptor, and pharmaceutical composition comprising same." This invention describes a modified IgE Fc receptor that has a high content of sialic acid. The polypeptide dimer demonstrates excellent safety and persistence in the body compared to conventional anti-IgE antibodies. It also exhibits strong binding to IgE, providing the advantage of an extended administration cycle. Importantly, this polypeptide dimer is an IgE single target substance and does not bind to an Fc gamma receptor, making it a promising candidate for the prevention or treatment of allergic diseases.

Career Highlights

Kyungwha Lee is associated with Gi Innovation, Inc., where he continues to advance his research and development efforts. His innovative approach to allergy treatment has positioned him as a key figure in the pharmaceutical industry.

Collaborations

He collaborates with notable colleagues, including Myoung Ho Jang and Bo-Gie Yang, to further enhance the impact of his research.

Conclusion

Kyungwha Lee's contributions to the field of allergy treatment through his innovative patent highlight his commitment to improving patient outcomes. His work exemplifies the potential of scientific advancements in addressing pressing health challenges.